



Correction: External control arms for rare diseases: building a body of supporting evidence

Artak Khachatryan¹ · Stephanie H Read¹ · Terri Madison¹

Published online: 19 January 2024
© The Author(s) 2024

Correction to: Journal of Pharmacokinetics and Pharmacodynamics (2023) 50:501-506
<https://doi.org/10.1007/s10928-023-09858-8>

In this article, under the section heading ‘Blinatumomab case study’ third paragraph should have been read as below:

To provide further support of the efficacy of blinatumomab relative to existing therapies, findings from a model-based meta-analysis study (‘synthetic control arm’) were presented. Data from 21 clinical studies published between 1995 and 2012 were manually extracted and used to develop mixed-effects meta-analysis models. In hindsight, this process can be substantially streamlined when using databases such as Certara’s Clinical Outcomes Database Explorer (CODEx) Clinical Trial Outcomes Databases [1]. The blinatumomab models were subsequently used to simulate the effect of blinatumomab relative to existing salvage therapies. The estimated CR rate of existing therapies was 13% (95% CI 4%–34%) and the odds ratio of CR for blinatumomab compared to existing therapies was 3.50 (95% CI: 1.63–8.40) [2].

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,

as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Certara (2023) 19/03/2023] CODEx. ; Available from: <https://codex.certara.com>
2. Przepiorka D et al (2015) FDA approval: Blinatumomab. Clin Cancer Res 21(18):4035–4039

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10928-023-09858-8>.

✉ Artak Khachatryan
Artak.Khachatryan@certara.com

¹ Evidence and Access, Certara, UK